The intersection of telemedicine platforms, diagnostic testing laboratories, and offshore call centers represents one of the largest targets of federal health care fraud enforcement in United States history.

Federal task forces—including the Department of Justice (DOJ) Health Care Fraud Strike Force, the Department of Health and Human Services Office of Inspector General (HHS-OIG), and the Federal Bureau of Investigation (FBI)—have executed sweeping national takedowns focusing on non-compliant diagnostic laboratory practices.

These investigations focus on Cancer Genomic (CGX) testing, Pharmacogenomic (PGX) testing, and high-complexity toxicology laboratories.

Due to substantial Medicare reimbursement rates—often ranging from $6,000 to over $18,000 per multi-gene testing panel—laboratories that rely on telemarketing leads, automated doctor sign-offs, and volume-based marketing models face catastrophic legal exposure.

What Is Telemedicine Laboratory Fraud?

Telemedicine laboratory fraud involves uncertified or non-compliant operational arrangements between diagnostic testing facilities, telehealth platforms, marketers, and ordering physicians to generate high-volume, medically unnecessary diagnostic claims submitted to federal health care programs:

“It shall be unlawful to knowingly and willfully offer, pay, solicit, or receive any remuneration (including any kickback, bribe, or rebate) directly or indirectly, overtly or covertly, in cash or in kind to induce or in return for referring an individual to a person for the furnishing or arranging for the furnishing of any item or service for which payment may be made in whole or in part under a Federal health care program...” — 42 U.S.C. § 1320a-7b(b) (Anti-Kickback Statute)

Under federal law, any diagnostic claim submitted to Medicare, Medicaid, or TRICARE that results from an illegal kickback or lacks an established practitioner-patient relationship is considered a false or fraudulent claim.

What Triggers Federal Investigations into CGX, PGX, and Diagnostic Labs?

Federal prosecutors and CMS data-mining algorithms continuously monitor lab billing trends for specific procedural and financial "red flags". Laboratories usually draw federal enforcement scrutiny through four primary operational practices:

1. Reliance on Offshore Call Centers and Aggressive Telemarketing

Federal agencies heavily scrutinize laboratories that acquire patient leads through aggressive, cold-calling telemarketing campaigns. Call centers routinely contact elderly Medicare beneficiaries, offer "free" swab kits under the guise of preventive health screenings, and collect personal Medicare identification numbers without a prior physician referral.

2. Sham Telemedicine Encounters and "Signature Mill" Approvals

To bill for CGX or PGX tests, a licensed physician or nurse practitioner must order the test based on documented medical necessity.

Federal investigations frequently uncover "signature mills"—telehealth platforms that pay clinicians $20 to $50 per consultation to review pre-populated patient files and electronically sign lab requisitions without ever speaking to, evaluating, or establishing a legitimate treatment relationship with the patient.

3. Lack of Clinical Individualization and Medical Necessity

CGX (cancer genetic) testing is clinically indicated only for individuals with specific personal or familial cancer histories, while PGX (pharmacogenomic) testing requires clear clinical indications regarding how a patient metabolizes specific prescription medications.

Laboratories that automatically perform broad multi-gene panels on every incoming swab—regardless of patient medical history—commit billing fraud by claiming reimbursement for medically unnecessary diagnostic tests.

4. Percentage-Based and Per-Sample Marketer Compensation

Paying third-party marketers, sales representatives, or telehealth companies a fee calculated per completed swab, per signed order, or as a percentage of insurance reimbursement directly violates the Anti-Kickback Statute (AKS) and the Eliminating Kickbacks in Recovery Act (EKRA).

The government views volume-based financial arrangements as illegal remuneration intended to induce patient referrals. 

Which Key Federal Statutes Apply to Telemedicine Laboratory Investigations?

Federal task forces combine civil, criminal, and administrative statutes to investigate, prosecute, and seize assets from non-compliant diagnostic testing labs:

How Do Whistleblower (Qui Tam) Lawsuits Expose Laboratory Telemedicine Schemes?

A massive percentage of federal CGX and PGX testing investigations originate from confidential Qui Tam whistleblower lawsuits.

Under 31 U.S.C. § 3730, private individuals—commonly former laboratory billing specialists, intake coordinators, sales reps, or participating clinicians—file sealed complaints on behalf of the government.

• Financial Relator Rewards: Whistleblowers who expose laboratory fraud are legally entitled to receive between 15% and 30% of the total civil recovery collected by the Department of Justice.

• Sealed Investigations: While the lawsuit remains under seal, federal agents execute target letters, audit billing trails, serve Civil Investigative Demands (CIDs), and issue grand jury subpoenas to gather evidence before filing public charges.

What Defense Strategies Protect Laboratories and Executive Leadership?

When a CGX, PGX, or diagnostic laboratory faces a federal investigation, Civil Investigative Demand (CID), or payment suspension, defense counsel must establish an aggressive, multi-tiered defense strategy:

• Challenging the Mental State (Scienter) Requirement: Under the False Claims Act and 18 U.S.C. § 1347, the government must prove actual knowledge, deliberate ignorance, or reckless disregard. Demonstrating that billing discrepancies arose from honest administrative confusion, complex Medicare Local Coverage Determinations (LCDs), or software coding glitches negates statutory criminal intent.

• Establishing Independent Medical Necessity: Using board-certified geneticists and clinical pathology experts to audit medical records and show that testing panels were clinically justified by patient risk factors rather than marketing volume.

• Structuring Safe Harbor & Fair-Market-Value Contracts: Reviewing marketing contracts and telehealth service agreements to prove compensation was based on documented, fair-market-value (FMV) administrative services rather than per-lead or per-sample referral metrics.

• Demonstrating Materiality Under Federal Precedent: Showing that technical administrative or documentation omissions were non-material to Medicare's ultimate decision to reimburse the claims.

• Invoking Advice of Counsel: Proving that laboratory leadership consulted qualified healthcare regulatory attorneys and structured its telehealth partnerships in good-faith reliance on written legal advice provides a complete defense against "knowing" statutory violations.

What Are Related Federal Crimes Charged in Laboratory Fraud Cases?

Understanding related federal charges matters because prosecutors routinely stack financial, identity theft, and conspiracy counts alongside civil and criminal healthcare fraud complaints during nationwide enforcement task force operations.

• Aggravated Identity Theft (18 U.S.C. § 1028A): This statute matters because using a Medicare beneficiary's personal identification number without lawful authority to submit claims for unauthorized genetic tests carries a mandatory consecutive 2-year prison sentence.

• Wire Fraud and Mail Fraud (18 U.S.C. §§ 1341, 1343): These charges matter because submitting electronic claims across state lines or receiving mailed Medicare reimbursement checks during an alleged testing scheme triggers independent wire/mail fraud counts carrying up to 20 years in federal prison per count.

• Conspiracy to Defraud the United States (18 U.S.C. § 371 / § 1349): This charge matters because prosecutors use conspiracy statutes to target laboratory owners, marketers, call center operators, and ordering physicians under a unified criminal indictment.

• Money Laundering (18 U.S.C. § 1956): This offense matters because transferring, depositing, or distributing proceeds derived from illegal healthcare billing leads to immediate asset forfeiture, bank account seizures, and additional long-term prison sentences.

Frequently Asked Questions (FAQs)

What is the primary difference between CGX and PGX testing under Medicare rules?

CGX (Cancer Genomic) testing analyzes inherited gene mutations to determine an individual's lifetime risk of developing specific cancers. PGX (Pharmacogenomic) testing analyzes gene variants to predict how a patient metabolizes certain medications. Both require strict adherence to Local Coverage Determinations (LCDs) establishing medical necessity before Medicare will cover the claims.

Can a laboratory be held liable if a telemedicine doctor ordered an unnecessary test?

Yes. Federal prosecutors hold laboratory owners and operators responsible for the claims they submit. If a laboratory knew, or acted in deliberate ignorance, that a telemedicine platform was supplying pre-signed or non-compliant orders without genuine physician-patient consultations, the laboratory faces False Claims Act and criminal healthcare fraud liability.

What happens if Medicare issues a Payment Suspension against my laboratory?

A Medicare Payment Suspension immediately freezes all incoming Medicare reimbursements during an active investigation. Payment suspensions are administrative actions based on credible allegations of fraud. Laboratories must act immediately through counsel to challenge the underlying allegations, submit rebuttal evidence, and avoid total operational insolvency.

Are volume-based marketing commissions legal if applied only to private insurance?

No. While the federal Anti-Kickback Statute (AKS) traditionally targets federal healthcare programs, the Eliminating Kickbacks in Recovery Act (EKRA) explicitly criminalizes paying or receiving volume-based, per-sample referral compensation for laboratory services regardless of whether the payor is public or private insurance.

Can laboratory owners face prison time even if they didn't directly talk to patients?

Yes. Laboratory owners and executives are primary targets in federal enforcement actions. Under federal conspiracy and corporate officer doctrines, owners can be convicted of healthcare fraud and money laundering if they designed, financed, or profited from non-compliant telemedicine marketing funnels.

How far back can the federal government audit CGX and PGX billing records?

Under the civil False Claims Act, the federal government or whistleblowers can audit billing records and pursue financial recoveries dating back 6 years, and in certain situations involving government intervention or concealed fraud, up to 10 years.

How Can Eisner Gorin LLP Help You?

Navigating a federal laboratory fraud investigation, responding to an OIG Civil Investigative Demand (CID), or challenging a CMS Medicare payment suspension requires immediate, highly specialized legal representation.

Our federal healthcare defense team represents laboratory owners, medical directors, clinical pathologists, and telemedicine executives nationwide.

Here is how our legal team protects your laboratory, professional standing, and personal freedom:

• Immediate CID, Subpoena, and Target Letter Defense: We handle all communications with the Department of Justice (DOJ), HHS-OIG, FBI, and federal prosecutors, ensuring full statutory compliance while protecting privileged corporate records and limiting document exposure.

• Challenging CMS Payment Suspensions: We file formal administrative rebuttals to combat payment freezes and restore vital cash flow to operating clinical facilities.

• Conducting Comprehensive Compliance Audits: We review medical-necessity documentation, billing workflows, and marketer contracts to identify vulnerabilities and implement corrective action plans.

• EKRA & AKS Contract Restructuring: We audit marketing agreements, sales commissions, and telehealth partnership contracts to ensure full compliance with statutory safe harbor provisions.

• Defending Against Whistleblower (Qui Tam) Lawsuits: We investigate relator allegations filed under seal, building a strong factual defense to persuade federal prosecutors not to intervene in civil actions.

If your testing laboratory or telehealth company has received a federal audit, CID, or grand jury subpoena, early legal intervention is critical. Contact our federal healthcare defense office at Eisner Gorin LLP today for a confidential consultation.

Related Legal Topics

• Telemedicine Fraud Explained
• Federal False Claims Act Guide
• New DOJ Fraud Division
• Inspector General Subpoenas